ORIC Pharmaceuticals Inc (ORIC) is a biopharmaceutical company specializing in the development of treatments for cancer. The company focuses on targeting resistance mechanisms in cancer that are not addressed by existing therapies. ORIC is committed to advancing its pipeline of innovative therapies and utilizing cutting-edge technical analysis tools to support its drug development efforts.

Technical analysis plays a crucial role in the evaluation of ORIC Pharmaceuticals Inc's stock. Several key technical indicators are utilized to assess the stock's performance and provide insights to investors. RSI (Relative Strength Index) is a popular indicator that measures the speed and change of price movements. By analyzing the RSI, investors can determine if a stock is overbought or oversold, indicating potential buying or selling opportunities.

ORIC Pharmaceuticals  (ORIC) Technical Analysis

Seo Title: ORIC Pharmaceuticals Inc Technical Analysis 

Meta Description: Learn about ORIC Pharmaceuticals Inc's technical indicators including RSI, ADX, MACD, ROC, STOCHRSI, WILLR. Find out the latest analysis and ratings for ORIC stock.

ORIC Pharmaceuticals Inc Technical Analysis: ORIC Stock RSI, ADX, MACD, ROC, STOCHRSI, WILLR

ORIC Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, discovers and develops therapies for treatment of cancers in the United States. Its clinical stage product candidates include ORIC-533, an orally bioavailable small molecule inhibitor of CD73 being developed for resistance to chemotherapy- and immunotherapy-based treatment regimens; ORIC-944, an allosteric inhibitor of the polycomb repressive complex 2 for prostate cancer; and ORIC-114, a brain penetrant orally bioavailable irreversible inhibitor designed to selectively target epidermal growth factor receptor and human epidermal growth factor receptor 2 with high potency towards exon 20 insertion mutations. The company is also developing multiple discovery stage precision medicines targeting other cancer resistance mechanisms. ORIC Pharmaceuticals, Inc. has a license and collaboration agreement with Voronoi Inc.; a license agreement with Mirati Therapeutics, Inc.; and clinical development collaboration agreement with Pfizer Inc. The company was incorporated in 2014 and is headquartered in South San Francisco, California.

ORIC Pharmaceuticals 

NASDAQ

This suggests that the technical indicators do not strongly favor either a buying or selling stance. In such cases, investors may need to rely on additional fundamental or market analysis to make a well-informed decision.

Balanced or Uncertain

MACD

WILLR

STOCHRSI

Free

is to help users identify stocks that trade at a low value relative to their fundamentals. Suitable for value investors such as Warren Buffet.

Name	Value	Action	infoPnL (10y)
auto_graphRSI	57.22	Neutral	-
auto_graphMACD	16.83	Neutral	317.0%
auto_graphCCI	41.96	Neutral	-12.7%
auto_graphADX	19.11	Neutral	-
auto_graphATR	23.46	Buy	-
auto_graphWILLR	-39.50	Neutral	7.5%
auto_graphROC	10.09	Buy	-99.6%
auto_graphSTOCHRSI	37.32	Neutral	380.4%

Buy	2	-75.00%
Hold	6	-25.00%
Sell	0	-100.00%

Trendlines, Support and Resistance

Welcome to Stocklytics

Technical Indicators

Indicator Ratings

Balanced or Uncertain

ORIC Pharmaceuticals (ORIC) Technical Analysis

Keep an eye on ORIC Pharmaceuticals

Frequently Asked Questions

What are the technical signals for ORIC Pharmaceuticals (ORIC) stock based on the last 30 days?

Take Your Investments to a Whole New Level